Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev. argent. cardiol ; 90(4): 265-272, set. 2022. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1441148

RESUMO

RESUMEN Introducción: La hipertensión pulmonar (HP) abarca un grupo heterogéneo de enfermedades que genera discapacidad y aumento de la morbimortalidad. La rehabilitación cardiorrespiratoria (RC) es un recurso terapéutico subutilizado en esta condición. Objetivo: Estimar los efectos de un programa de RC en una prueba de caminata de campo y en la calidad de vida de pacientes con diagnóstico de HP de los grupos I y IV. Materiales y Métodos: Los pacientes fueron evaluados antes y después de la intervención mediante la prueba de caminata de 6 minutos (PC6M) y el Saint George's Respiratory Questionnaire (SGRQ). El programa de RC consistió en 8 semanas de ejercicios supervisados con modalidad institucional. Resultados: Se incluyeron 19 pacientes con diagnóstico de HP precapilar por cateterismo cardíaco derecho, 18 mujeres (94,7%) con una media de edad de 45,5 ± 14,3 años. Trece (68,4%) presentaron HP del grupo I, y 6 (31,6%) HP del grupo IV. Se observaron cambios estadísticamente significativos en la PC6M (diferencia de medias -DM- 31 ± 27,3 metros; p <0,001), y en el SGRQ (DM 8,2 ± 10,2; p<0,01). No se reportaron eventos adversos graves durante el programa. Conclusiones: Nuestro estudio sugiere que un programa de RC supervisado en pacientes con HP podría mejorar la distancia caminada y la calidad de vida.


ABSTRACT Background: Pulmonary hypertension (PH) comprises a heterogeneous group of diseases resulting in disability and increased morbidity and mortality. Cardiopulmonary rehabilitation (CR) is a therapeutic resource not widely used in this condition. Objective: The aim of this study was to evaluate the effects of a CR program on a walking test and on the quality of life in patients with group 1 and group 4 PH Methods: Patients were evaluated before and after the intervention with the six-minute walk test (6MWT) and Saint George's Respiratory Questionnaire (SGRQ). The program consisted of 8 weeks of supervised exercises within the institution. Results: Nineteen patients with precapillary PH diagnosed by right heart catheterization were included; 18 were women (94.7%) with a mean age of 45.5±14.3 years. Thirteen (68.4%) patients had group 1 PH and 6 (31.6%) had group 4 PH. There were statistically significant changes in the 6MWT [mean difference (MD) 31±27.3 m; p<0.001], and in the SGRQ (MD 8.2±10.2; p<0.01). No adverse events were reported during the program. Conclusions: Our study suggests that a supervised CR program in patients with PH could improve the distance walked and the quality of life.

2.
BMC Pulm Med ; 19(1): 258, 2019 Dec 21.
Artigo em Inglês | MEDLINE | ID: mdl-31864342

RESUMO

BACKGROUND: There is little information about vitamin D (Vit D) deficiency in patients with pulmonary hypertension (PH). The objective of this study was: 1) compare Vit D levels between patients with PH, left ventricular failure (LVF) and healthy subjects (HS); 2) correlate, in patients with PH, Vit D levels with prognosis-related variables, such as the 6-min walk test (6MWT). METHODS: Vitamin D levels were measured in a cross-sectional study in 126 patients from one of three groups: patients with PH (n = 53), patients with LVF (n = 42) and healthy subjects (n = 31). In all groups, 8-h fasting blood samples were obtained in the morning. In the PH and the LVF group, functional class (WHO criteria), metres covered in the 6MWT and echocardiographic parameters were analysed. In the PH group, plasma N terminal pro B type natriuretic peptide (NT-proBNP) level was analysed and a complete haemodynamic evaluation by right heart catheterisation was made. RESULTS: Mean Vit D levels were lower in PH than in both other groups (ng/ml, mean ± SD): PH 19.25 ± 10, LVF 25.68 ± 12, HS 28.8 ± 12 (PH vs LVF p = 0.017, PH vs HS p = 0.001 and HS vs LVF p = 0.46). Vit D deficiency prevalence was higher in PH as compared to the other groups (PH 53.8%, LVF 45.2%, HS 25%, p = 0.01). Patients with PH in functional class (FC; WHO criteria) III-IV had higher Vit D deficiency prevalence than those in FC I-II (86.7% vs 40.5%, p = 0.003). There was a significant linear correlation between the 6MWT and Vit D levels in PH (p < 0.01), but not in LVF (p = 0.69). CONCLUSIONS: Vit D levels were lower in patients with PH as compared to patients with LVF and HS and correlated directly with 6-min walk distance.


Assuntos
Hipertensão Pulmonar/epidemiologia , Deficiência de Vitamina D/epidemiologia , Adulto , Idoso , Estudos de Casos e Controles , Estudos Transversais , Ecocardiografia , Feminino , Insuficiência Cardíaca/epidemiologia , Humanos , Hipertensão Pulmonar/sangue , Hipertensão Pulmonar/fisiopatologia , Masculino , Pessoa de Meia-Idade , Peptídeo Natriurético Encefálico/sangue , Fragmentos de Peptídeos/sangue , Prevalência , Prognóstico , Disfunção Ventricular Esquerda/epidemiologia , Vitamina D/análogos & derivados , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Teste de Caminhada , Adulto Jovem
3.
Rev. argent. cardiol ; 87(3): 186-190, mayo 2019. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1057340

RESUMO

RESUMEN Objetivos: Evaluar la prevalencia del déficit de hierro en hipertensión pulmonar y compararlo con otras poblaciones de pacientes. Establecer su valor pronóstico. Material y métodos: Estudio prospectivo, observacional. Se midieron parámetros de hierro sérico en pacientes consecutivos con diagnóstico de hipertensión pulmonar. Se compararon con pacientes con insuficiencia cardíaca y con controles sanos. Se buscó correlación entre los valores séricos de hierro y la clase funcional, la distancia recorrida en TC6M y el NT-proBNP. Resultados: Participaron 107 pacientes: 60 con hipertensión pulmonar, 26 con insuficiencia cardíaca y 21 controles sanos. El déficit de hierro fue del 78,3% en los pacientes con hipertensión pulmonar; del 45,8%, en aquellos que presentaban insuficiencia cardíaca; y del 23,8% (p < 0,001) en los controles sanos. La prevalencia de anemia resultó del 25% en los pacientes con hipertensión pulmonar; del 26,9% en los que padecían insuficiencia cardíaca; y del 19% (p < 0,8) en los controles sanos. En el subgrupo de pacientes en clase funcional I-II, la prevalencia de DFe fue del 78% en los pacientes con hipertensión pulmonar vs. el 43,5% (p < 0,005) en los que tenían insuficiencia cardíaca, y la anemia resultó del 17,1%% vs. el 28%% (p < 0,2). Se halló correlación significativa entre ferremia y saturación de transferrina con distancia caminada en TC6M (r: 0,35; p < 0,01 y r: 0,34; p < 0,01) y no hubo correlación para ferritina y transferrina. No se encontró significancia estadística entre déficit de hierro y clase funcional o NT-proBNP. Conclusiones: El déficit de hierro en la hipertensión arterial es altamente prevalente y superior al observado en la insuficiencia cardíaca y en los sujetos control, y no se establece relación con prevalencia de anemia, la cual fue similar en los tres grupos. El hierro sérico tiene una clara relación con la distancia caminada, no así con clase funcional, lo que, tal vez, obedezca al bajo número de pacientes.


ABSTRACT Objective: The aim of this study was to assess the prevalence of iron deficiency in pulmonary hypertension, to compare it with other patient populations and to establish its prognostic value. Methods: This was a prospective, observational study. Serum iron parameters were measured in consecutive patients diagnosed with pulmonary hypertension and compared with heart failure patients and healthy controls. A correlation was sought between serum iron levels and functional class, distance walked in the 6-minute walk test and NT-proBNP. Results: A total of 107 patients were included in the study: 60 with pulmonary hypertension, 26 with heart failure and 21 healthy controls. Iron deficiency was 78.3% in patients with pulmonary hypertension, 45.8% in those with heart failure and 23.8% in healthy controls (p<0.001). The prevalence of anemia was 25% in pulmonary hypertension, 26.9% in heart failure and 19% in healthy controls (p<0.8). In patients with functional class I-II, iron deficiency was: 78% in pulmonary hypertension vs. 43.5% in heart failure (p<0.005), and anemia was 17.1% vs. 28%, respectively (p<0.2). A significant correlation was found between serum iron and transferrin saturation with the distance walked in the 6-minute walk test (r: 0.35; p<0.01 and r: 0.34; p<0.01, respectively) and no correlation was found for transferrin and ferritin. Also, no significant correlation was found between iron deficiency and functional class or NT-proBNP. Conclusions: Iron deficiency is highly prevalent in pulmonary hypertension, and superior to that found in heart failure patients and healthy controls. No relationship was established with anemia, which was similar in the three groups. Serum iron is clearly related with the distance walked, but not with functional class, a result which may be attributed to the limited number of patients.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...